The authors suggested MutL loss as a predictive marker of sensitivity to combinatorial treatment with endocrine intervention and HER inhibitors in endocrine treatment-resistant ER+/HER2− breast cancer patients.
[Nature Communications]
Sorry, but the selected Zotpress account can't be found.